The report on the Organ-on-a-Chip market provides an in-depth analysis of the market size, forecasts, and opportunities of Organ-on-a-Chip catering to the multiple key segments – Lung-on-Chip, Heart-on-Chip, Liver-on-Chip, Intestine-on-Chip, Kidney-on-Chip, Human-on-Chip, Placenta-on-Chip, Brain-on-Chip, Gut-on-Chip, Nerve-on-Chip, Others. The study also includes market analysis of Organ-on-a-Chip segments across five regions – North America, Europe, Asia-Pacific, Central and Latin America (CALA), and Middle-East and Africa (MEA).Organs-on-Chips: A $1 Billion Market in the Next Decade
This Organ-on-a-Chip market report also includes insights into key market requirements gathered from scientists, medical professionals, bioengineers, researchers, biotechnology companies, pharmaceutical, cosmetics and chemical companies. The report also provides their preferences, priorities, and perception of adoption of Organ-on-a-Chip across regions. The analysis in this report will help market participants, vendors, suppliers, distributors, and resellers to develop strategies, marketing goals and business decisions based on the actionable market intelligence from this report.
This report has been built on a rigorous period of information gathering from both secondary and primary sources through several interviews with industry participants, technology developers, and regulators. Data gathered from these interviews and surveys was curated, analyzed, and engineered to understand buying, spending, demand, and supply patterns and to estimate market sizes and forecasts. The resultant data was checked for applicability across value chains through market-data associations and then further validated through multiple check points to check consistencies, error samples, variances. The 2018 syndicated study report on the Organ-on-a-Chip market is part of an ongoing series of market reports that focus on micro emerging trends in the healthcare markets across multiple regions and countries.
Questions answered in the report
- What is the current size of the market?
- What is the market opportunity for technologies?
- What are the companies in this space and what do they offer?
- What are the perceptions of technologies among users?
- How ready is the market for new technologies and solutions?
Table of Contents
Samples
LOADING...
Executive Summary
Drug and pharmaceutical companies lose billions of dollars due to high drug failure rates in clinical trials, largely due to the current limitations of using animal models and static cell culture systems. Coupled with this is the fact that the in-vitro modeling and therapy development for many diseases is not accurate. This creates a direct need for clinical modeling that is physiologically relevant to human organs and at the same time intuitively integrating human-derived cells with sensor-driven OOC systems.
However, complexities of organ functions aren’t easy to model. Creating an OOC system is a complicated process with multiple hurdles to cross. Firstly, there is a major need to accurately reproduce the architectural complexity of organs and tissues in vitro. Then, there is a bigger need to accurately link them in the correct format for the connected systems to recapitulate tissue-organ interactions. Solving this is set to be industry’s key priority. OOCs provide tremendous potential if commercialization is aided by collaborative efforts across the value-chain and ecosystem. Regulators, medical professionals, scientists, technicians, and organizations need to collaborate to usher in the future of medicine through OOCs.
Challenges aside, OOCs offer a possible opportunity to replace current animal based testing and assessments over time. However, it is unlikely that OOCs are comprehensive enough to make that change during the forecast period due to the traditional regulatory requirements and complexities of organ functions. The current forecast period is the earliest phase of market adoption for organ-on-a-chip players. The next decade is a favorable period for upward trend in regulation, ratification, and adoption. The use of OOCs, as a viable alternative to traditional clinical lab options, in an improving regulatory environment and increasing marketplace acceptance, promises to lay the foundation of the future of accurate medicine.
OOCs are a key piece in the future of personalized medicine, and collaborative efforts across the ecosystem are key to ensure widespread adoption. The market opportunity for Organ-on-a-Chip across the globe is considerable overall.
Companies Mentioned
- 4Dcell
- AxoSim Techologies LLC
- CN Bio Innovations
- Cherry Biotech SAS
- Elvesys
- Emulate
- Hepregen
- Hesperos
- HµREL
- Insphero
- Micronit Microtechnologies B.V.
- Mimetas
- Nortis
- Organovo Holdings Inc.
- Sophion Bioscience
- Tara Biosystems
- thinXXS Microtechnology AG
- TissUse